4Mass Spólka Akcyjna (4MS) Fair Value & Analysis
Consumer Defensive · PL · Market cap 103M PLN
Fair value as of: Jun 25, 2026
Analysis
4Mass Spólka Akcyjna (4MS) currently trades at 4.80 PLN, while our model-based Fair Value estimate is 9.87 PLN — implying the stock looks roughly 105.6% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
4Mass Spólka Akcyjna engages in the manufacture and distribution of make-up products. The company provides hybrid varnishes and accessories essential for hand and foot care under the Claresa brand; professional equipment, stainless steel beauty tools, and accessories for complementary nail care and design products under the Stylistic brand; and design, hand, and foot care products, as well as equipment and furniture used by professional manicure and pedicure salons under the Palu brand. It also manufactures three-layer type 1 medical masks; disinfectants and personal protection products; and imports accessories and products used across the cosmetics industry. The company offers its products through drugstores, hypermarkets, discount stores, beauty salons, spas, and referral marketing. 4Mass Spólka Akcyjna was incorporated in 2017 and is based in Wolomin, Poland.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is 4Mass Spólka Akcyjna (4MS) undervalued?
What is the fair value of 4MS?
What is the quality score of 4MS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.